Insider transactions

Kevin Tang

CIK 1178579 · Chief Executive Officer · last filed 2026-08-28

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$228.35M
Companies
13
Total Filings
78
Lifetime Open-Market Net
$167.23M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

HRTX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
4747 EXECUTIVE DRIVE
SUITE 210
SAN DIEGO, CA 92121
Formerly Known As
TANG KEVIN C (2002–2024)
Related Filers
TANG CAPITAL MANAGEMENT LLC — 217 joint filings, latest 2026-08-28
TANG CAPITAL PARTNERS LP — 205 joint filings, latest 2025-02-27
LA JOLLA PHARMACEUTICAL CO — 38 joint filings, latest 2022-08-24
John G Lemkey — 29 joint filings, latest 2020-09-30
Michael S Hearne — 21 joint filings, latest 2022-08-24
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BOLD 10%+ Owner 2,840,635 $2.41 $6.85M -$108.7K 1 2026-08-28
AUPH Director 12,229,500 $17.04 $208.39M $49.81M 4 2026-03-03
TCR2 THERAPEUTICS INC. (TCRR) Delisted 10%+ Owner 4,338,617 $1.48 $6.42M $262.9K 1 2023-05-15
Jounce Therapeutics, Inc. (JNCE) Delisted Director 10,000 $1.88 $18.8K $0 1 2023-05-05
LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Director 10,049,224 $6.22 $62.51M $108.22M 16 2022-01-14
Odonate Therapeutics, Inc. (ODT) Delisted Chief Executive Officer 15,375,428 $1.12 $17.22M $181.59M 13 2020-12-23
HRTX Director 5,806,751 $0.30 $1.75M -$194.04M 10 2019-12-23
Ardea Biosciences, Inc./DE (RDEA) Delisted Director 0 — — $21.77M 8 2012-06-20
PENWEST PHARMACEUTICALS CO (PPCO) Delisted 10%+ Owner 0 — — $0 1 2010-09-22
VNDA 10%+ Owner 2,884,671 $3.94 $11.37M -$3.12M 3 2010-01-13
HERON THERAPEUTICS, INC. /DE/ (APPA) Delisted 10%+ Owner 16,496 — — $1.82M 2 2008-12-22
ARADIGM CORP (ARDM) Delisted 10%+ Owner 13,500 — — $18.0K 1 2008-10-15
NEOSE TECHNOLOGIES INC (NTEC) Delisted 10%+ Owner 487,506 $9.63 $4.69M $995.6K 1 2008-09-22

Recent Filings · Page 2 of 8

78 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-06-01 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Buy (P) +980,080 $4.38M EDGAR
2021-05-26 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Buy (P) +1,594,856 $6.31M EDGAR
2021-05-04 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) — $0 EDGAR
2020-12-23 Odonate Therapeutics, Inc. (ODT) Delisted Buy (P) +1,103,136 $16.72M EDGAR
2019-12-23 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) — $0 EDGAR
2019-12-23 HRTX Grant (A) — $0 EDGAR
2019-10-07 HRTX Buy (P) +285,714 $5.00M EDGAR
2019-06-18 Odonate Therapeutics, Inc. (ODT) Delisted Buy (P) +250,000 $6.54M EDGAR
2019-06-05 Odonate Therapeutics, Inc. (ODT) Delisted Buy (P) +468,460 $11.68M EDGAR
2019-01-25 LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted Grant (A) — $0 EDGAR
Showing 11–20 of 78
Page 2 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.